A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Recruiting

UpadacitinibA Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

Sponsor:

CARE ARTHRITIS LTD.

Code:

NCT06454188

Conditions

Psoriatic Arthritis

Spondyloarthritis, Axial

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Upadacitinib 15 MG [Rinvoq]

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-07. This information was provided to ClinicalTrials.gov by CARE ARTHRITIS LTD. on 2025-05-29.